Syrma SGS — a good EMS boat learning to row uphill
Syrma SGS Technology Ltd
Snapshot
Syrma SGS makes electronics for other companies — it is a contract manufacturer (you bring the design, or it designs for you, and it builds the circuit boards and finished gadgets). It serves five buckets: industrial, automotive, healthcare (medical devices), consumer, and a fast-growing IT/railways slice. Market cap ₹25,724 cr, share price ₹1,334, a hair under its all-time high of ₹1,355 and up ~157% off last year’s ₹499 low. It trades at about 80 times last year’s earnings and 9 times book value. Last year it earned 13.9% on owners’ money (RoE) and 16.7% on all the capital in the business (RoCE). In one phrase: a Good, capital-hungry compounder in a hot industry — growing fast and well-run, but in a thin-margin trade, priced today like a sure thing.
As of 2026-06-20, from screener snapshot.
The verdict in two boxes — the business first, the price second
Keep them apart on purpose. Box 1 describes the company; it would read the same if the share price doubled or halved tomorrow. Box 2 is just what the market happens to charge for it today.
Box 1 — The business (durable):
| Lens | Result |
|---|---|
| Business-quality score | 14.5 / 23 (Quality 7.5/12 · Growth 5/6 · Longevity 4/5) |
| Buffett rubric | 5 / 10 PASS (3 PASS, 4 PARTIAL, 3 FAIL) |
| Business bucket | Good (healthy returns, but needs heavy capital to grow) |
| Wealth-creator type | Enduring tailwind · still-Volatile earnings (margins thin and swingy) |
| Economic Profit | ₹54 cr (RoE 13.9% − CoE 12% on ₹2,863 cr net worth) — barely creating value |
One line: A Good business riding a genuine tailwind, run by serious operators — but its returns sit only a whisker above the cost of its owners’ money, so it must keep growing fast to be worth much. That’s true regardless of today’s price.
Box 2 — The price today (a current phenomenon):
| Reading | Result |
|---|---|
| CMP | ₹1,334 (as of 2026-06-20) |
| Price pillar | 0.5 / 2 (PEG ~2.1x · payback ~6.3x) |
| Margin-of-safety band | ₹600–₹820 (where PEG nears 1x / payback gets sane) |
| Mr. Market’s mood now | Greedy — euphoric “India EMS supercycle” re-rating, fresh all-time high |
| CMP vs the band | Demanding — priced for years of flawless execution |
One line: Today the market is pricing Syrma rich — a mood driven by a roaring “Make-in-India electronics” narrative and a stellar Q4. That mood can cool next quarter without one bolt changing on the factory floor.
In plain English
Imagine a very good kitchen-for-hire. Restaurants (the brand owners) bring recipes; this kitchen cooks the food, plates it, and ships it. Syrma SGS is that kitchen for electronics. A car company needs the little circuit board behind your dashboard; a medical-device firm needs a monitor assembled; a laptop brand needs a motherboard populated — Syrma builds them. Increasingly it also designs the dish itself (they call this ODM — original design manufacturing — and it carries fatter margins than just cooking to someone else’s recipe). It has been doing this for forty years, exports to Europe and the US, and runs more than ten factories with over 10,000 people.
Here is the good news, and it’s real. The whole Indian electronics-manufacturing industry is in a once-in-a-generation boom — output has risen roughly sixfold in a decade, the government is pouring incentives into making things at home instead of importing from China, and Syrma is firing on every cylinder. Last year sales grew 27% to ₹4,819 cr, but profit nearly doubled (+87%) because the mix improved — more exports, more design work, more medical and defence. Even better, they fixed the one thing that used to scare people: cash. For two years this business burned cash even while reporting profits (a classic warning sign). In FY26 it threw off ₹290 cr of real operating cash, paid down debt, and ended the year with more cash than debt for the first time. That is a company growing up.
But now the catch, and it’s just as real. Electronics contract-manufacturing is, at bottom, a thin-margin trade. Syrma makes about 11 paise of operating profit on every rupee of sales, and only about 7 paise of net profit. It earns 13.9% on its owners’ money — and the cost of that money is roughly 12%. So for every ₹100 of shareholder capital, it creates barely ₹2 of true economic value above what the money costs. To grow, it must keep buying machines, building factories, and funding inventory — it is a “Good” boat (Buffett’s word for a business that earns decently but eats capital to grow), not a “Great” one (the kind that gushes free cash, like a soft-drink brand). Its big new bet — spending ₹800 cr-plus to make its own circuit boards (PCBs) instead of importing them — is a smart, government-backed move to climb the value ladder, but it is exactly the kind of capital-hungry swing that defines the “Good” category.
The moat is shallow but not absent. Syrma’s edge is forty years of relationships, a hard-won export track record, a real design (ODM) capability, and a genuine cost-and-quality obsession its boss talks about constantly. That keeps customers sticky and is why exports grew 41% last year. But there is no patent, no brand a consumer asks for by name, and no lock that stops a customer moving to a cheaper builder. And the neighbourhood is getting crowded — Dixon, Kaynes, Amber, and now giants like L&T are all piling into the same trade.
The one-line tension: this is a fundamentally Good business, run by people I’d trust, on a tailwind that is real. The problem is entirely the price. At 80 times earnings and 9 times book, the market is paying a Great-business price for a Good business. The whole question is whether the growth runway is long and clean enough to grow into that number — or whether you’re buying years of perfection up front.
Sitting down with the management
Dear reader — if you sat across the table from these two men for an afternoon, you’d come away impressed, and a little watchful.
The chairman, Sandeep Tandon, carries electronics in his blood. His father, Sirjang Lal Tandon, built Tandon Corporation in 1980s California into the world’s #1 disk-drive maker — Forbes 400, the works (HARD — Wikipedia, Tandon Corporation). Sandeep himself did time at Celetronix, an EMS firm later sold to Jabil, before building Syrma (MEDIUM — company/IIFL profile). The managing director, Jasbir Singh Gujral, is a chartered accountant with forty years in this exact trade and the founding promoter of SGS Tekniks, the North-India automotive-electronics house that merged in to create today’s company. So this isn’t a financier’s roll-up. It’s two lifelong hardware operators who genuinely love the factory floor — Gujral on the May 2026 call kept returning, unprompted, to working-capital days, frugality, and “the quality of growth,” not the growth itself. That is the right music.
How have they spent the owners’ money? Mostly sensibly. The 2022 IPO raised about ₹840 cr; the proceeds went into capacity, R&D and working capital, as promised. The bolt-on deals — Perfect ID (RFID), Johari Digital (medical devices, 51% for ₹229 cr in 2023), and now Elcome (defence and maritime electronics, 60% for ~₹235 cr, closed Dec 2025) — have each pushed the company up the margin ladder into higher-value niches. None were related-party deals to a promoter’s private vehicle; they were arms-length, which is a real positive. And here’s the tell that I liked most: in May 2026 they walked away from a solar JV (the K-Solare deal with Premier Energies) when the seller couldn’t meet conditions — “no material financial implications,” deal dropped, intent kept (MEDIUM — Energetica, SolarQuarter). The willingness to walk is the rarest discipline in capital allocation; Buffett would nod.
Do they talk straight? Largely, yes — and in a useful direction. They guide top-line high (30–35%) and sometimes land at the low end (FY26 came in at 27%), but they guide margins conservatively and then beat them (delivered ~12% against an 8–9% guide). A management that under-promises on the number that’s hard to control (margin) and over-reaches on the one that excites the market (growth) is being more honest than one that sandbags everything. The credit-rating agencies agree: India Ratings upgraded them to AA/Stable in May 2026 (HARD — Whalesbook/Machine Maker).
Now the watch-items, stated plainly. Promoter holding has slipped from ~47% to ~42% in a year — and that looks like a tell, but it isn’t a sale. It’s dilution from a ₹1,000 cr institutional share placement (a QIP, Aug 2025) that brought in HDFC Life, Tata AIA and Axis MF, with proceeds transparently spent on Elcome and debt repayment (HARD — Trendlyne, Business Standard). Promoter pledging is zero. So the integrity gate is clean. The genuine concerns are different: the pace of the spending spree (Elcome + Johari + the big PCB plant, all funded by a mix of debt and equity) raises real integration and execution risk; the business is structurally thin-margined no matter how well they run it; and Gujral, with forty years behind him, is likely in his sixties — succession rests partly on the professional CEO/CFO bench they’ve built (Satendra Singh, hired 2023; Bijay Agrawal), which de-risks it but doesn’t eliminate it.
Would Buffett and Agrawal shake hands on this management? Yes — these are honest, capable, owner-minded operators in a tough trade. What would change their mind: if the PCB capex slips badly or earns poor returns, if the acquisition pace outruns the balance sheet, or if promoter selling (as opposed to dilution) ever begins.
What’s on the horizon (live-issues tracker)
1. The PCB backward-integration bet — the crux. 🟡 Early.
What it is: Syrma is spending ₹800 cr-plus (some reports put the full multi-phase program near ₹1,600–1,800 cr, with a South Korean partner, Shinhyup) to make its own printed circuit boards — the bare green boards everything is built on — instead of importing them, mostly from China. It won a government incentive (the ECMS scheme) to do it. Phase one is ~₹400 cr; first production is targeted for late FY27/FY28.
Why it matters and why it’s the crux: this is the single bet that justifies — or fails to justify — the stock’s Great-business price tag. If it works, Syrma stops being “just an assembler” and owns a scarce, hard-to-build, higher-margin layer of the supply chain with a government moat around it. If it stumbles — and PCB fabs are capital-heavy, technically demanding, and historically low-return globally — it’s a ₹800 cr hole dug at the top of the cycle.
The mechanism, in plain terms. Today Syrma buys the bare board, then “stuffs” it with chips and components (assembly). The bare board is ~20–30% of the bill of materials and almost all of it is imported. By making the board itself, Syrma captures that slice and removes a supply-chain choke point. The closest analogy is a baker who, tired of importing flour, builds his own flour mill. Test the analogy: it holds where the mill earns a fair return and the baker has guaranteed demand for the flour — but a flour mill is a commodity business with its own brutal economics, and if global flour gets cheap, the mill becomes a millstone. PCB fabrication is exactly that kind of commodity-cyclical business worldwide. So the bet is strategic (security of supply, a value-chain rung) more than it is obviously high-return — and that’s the honest tension.
The named-competitor / named-threat map (the EMS trade Syrma actually competes in):
| Rival | Backed by / scale | Where they’re strong | Proof point |
|---|---|---|---|
| Dixon Technologies | ₹76,000 cr mcap; the giant | Mobiles, consumer (volume) | ₹49,000 cr sales, but ~4% margin — pure scale, thin |
| Kaynes Technology | ₹22,000 cr mcap | Aerospace, defence, medical IoT; OSAT/semis | 16% OPM, the high-margin specialist |
| Amber Enterprises | Large; PLI beneficiary | AC components, growing into EMS | Diversifying into Syrma’s turf |
| L&T | A ₹4-lakh-cr-plus conglomerate | Newly announced ~₹5,000 cr electronics capex | Deep-pocketed new entrant |
| Avalon, Cyient DLM | Smaller niche EMS | High-mix industrial / aerospace | Direct overlap on industrial export work |
The threat is real but bounded. Competition hits the commodity end (consumer, mobiles, simple assembly) hardest — exactly the slice Syrma is deliberately capping at ~30% of revenue. The high-value end it’s growing into (defence, medtech ODM, exports) is stickier and harder to enter. So the bet is with the current (India EMS, government tailwind, supply-chain reshoring) but against a crowding field where margins, sector-wide, are expected to drift down even as revenue booms.
The real-world precedent: the global EMS history is sobering. The world’s biggest contract manufacturers — Foxconn, Jabil, Flex — are vast but earn famously thin single-digit margins because the customer holds the power. India’s twist is that the components layer (PCBs, where Syrma is heading) is more protected and government-subsidised than bare assembly — which is precisely why this bet, if it lands, matters. But no precedent says PCB fabs are a goldmine; the honest read is they’re a defensive, strategic rung, not a fountain of free cash.
The honest verdict on the crux: not “too hard,” but genuinely two-sided. The strategy is right and the people are capable. But the price already assumes it works cleanly and earns well — and that’s the part the evidence cannot yet confirm. Watch the commissioning date and the first-year returns like a hawk.
2. Margins vs the supply-chain storm. 🟢 On track but guided cautiously. Management delivered ~12% EBITDA margin in H2 FY26 but is guiding FY27 down to 10.5–11%, blaming metal-price inflation and shipping disruption (Middle East routes). They have pass-through clauses with customers, but “not on day zero.” This is conservatism, not deterioration — they’ve out-delivered margin guidance before.
3. The Elcome (defence/maritime) integration. 🟡 Early. Closed Dec 2025; ~5% of revenue. High-margin, long-working-capital business (naval navigation, radar). Too soon to judge the integration, but it’s the right kind of acquisition — up the value ladder, not down.
The watch-list:
- PCB phase-1 commissioning — does it hit late-FY27/early-FY28, or slip? (the single most important date)
- Working-capital days — held at 63 (58 ex-Elcome); does it stay sub-65 or creep back toward 90 as defence/smart-metering scale?
- EBITDA margin — does FY27 hold ≥11%, beating the cautious guide again, or sink toward the commodity 8–9%?
- Operating cash flow — does the FY26 turn (₹290 cr positive) hold, or does the capex spree push it negative again?
- Promoter holding — dilution is fine; actual selling would be a red flag.
- ODM mix — holds/grows from 17%? (the margin lever)
QGLP scorecard (the Motilal Oswal lens) — the receipts
Each line scored 0 / 0.5 / 1 against the screener numbers. Business score = Quality + Growth + Longevity = /23. Price is reported separately below.
| # | Question | Score | Evidence |
|---|---|---|---|
| Quality of Business (6) | 3.5 | ||
| 1 | Large opportunity? | 1 | Global EMS TAM > $600bn; Syrma ~$0.5bn. Vast runway. (concall Jun-26) |
| 2 | Favourable industry structure? | 0 | Thin, competitive, customer-led; OPM only 6–11% and swingy. Crowding (Dixon, Kaynes, L&T). |
| 3 | Defensible moat? | 0.5 | 40-yr relationships, export track record, ODM design — real but shallow stickiness, no pricing lock. |
| 4 | Return ratios > 15% consistently? | 0.5 | RoCE 16.7%, RoE 13.9% (FY26). RoCE 15–17% most years but RoE rarely clears 15%; dipped to 10% FY24. |
| 5 | Asset-light / low capital intensity? | 0 | Capital-hungry: FCF negative FY22–24, capex heavy, ₹800cr PCB bet ahead. The “Good”-not-Great tell. |
| 6 | Favourable terms of trade (neg. working capital)? | 0.5 | Payable days (199) > debtor days (139) → suppliers part-fund it; but working-cap days rose 60→107. |
| Quality of Management (6) | 4.0 | (maps to Buffett 4–6; full read above) | |
| 7 | Unquestionable integrity? | 1 | Zero pledging; arms-length M&A; transparent QIP use-of-funds; no SEBI/auditor flags. (Trendlyne) |
| 8 | Proven execution track record? | 0.5 | Beats margin guidance; misses top-line guidance (27% vs 30–35%). Cash-flow turnaround delivered. |
| 9 | Growth mindset & vision? | 1 | Constant up-the-ladder push: ODM, exports, medtech, defence, own PCBs. Clear ambition. |
| 10 | Superior capital allocation? | 0.5 | Walked away from K-Solare (good); but acquisitive + capex-heavy at thin returns; RoE barely > CoE. |
| 11 | Clear succession plan? | 0.5 | Professional CEO/CFO bench (Singh 2023, Agrawal); MD likely 60s — key-man risk partly mitigated. |
| 12 | Minority interests protected? | 0.5 | Dividend payout falling (9%, ploughing back); QIP diluted but value-accretive. Fair, not generous. |
| Growth (6) | 5.0 | ||
| 13 | Structural sector tailwind? | 1 | India electronics output 6× in a decade; EMS growing well above GDP. Genuine winner-category. |
| 14 | Volume-led (sustainable) growth? | 1 | Driven by new customers, verticals, wallet-share — not price. 32 customers added FY26. |
| 15 | Operating leverage? | 1 | PAT +87% on sales +27% FY26; OPM 6%→11% over two years. Textbook leverage. |
| 16 | Manageable leverage? | 1 | Net cash (₹467 cr) at FY26 end, D/E 0.1x, AA rating. Balance sheet de-risked. |
| 17 | Market-share gain potential? | 1 | Explicitly gaining wallet-share; ranked ~#65 globally with huge headroom. |
| 18 | Earnings growth > 15% CAGR? | 0.5 | PAT 5-yr CAGR ~38% (HARD) — but margin-thin and cyclical, so durability of >15% is the question. |
| Longevity (5) | 4.0 | ||
| 19 | Relevant for next 10–15 years? | 1 | Electronics-in-everything is a durable, structural demand. Not disruption-prone at the trade level. |
| 20 | Can extend its moat period (CAP)? | 0.5 | PCB backward-integration could widen the moat — but unproven, and the spread over CoE is thin. |
| 21 | Can sustain growth period (GAP)? | 1 | Tiny share of a vast, under-penetrated market. Decade-plus runway. |
| 22 | Geographic / product diversification headroom? | 1 | Five verticals + exports + defence + PCBs + renewables intent. Plenty of optionality. |
| 23 | Adaptive, resilient culture? | 0.5 | Great-Place-to-Work certified, frugality-obsessed DNA; but young as a listed entity, untested through a downcycle. |
| BUSINESS-QUALITY SCORE | 14.5 / 23 | Quality 7.5 · Growth 5.0 · Longevity 4.0 | |
| Price (2) — reported separately | 0.5 | ||
| 24 | Valuation reasonable (PEG)? | 0.5 | P/E ~80; PEG ~2.1x on 5-yr PAT growth. Expensive, not absurd given growth. |
| 25 | Margin of safety (PEG<1 / payback<1)? | 0 | 5-yr payback ~6.3x; PEG ~2x. No margin of safety at CMP. |
| (Canonical QGLP total, for fidelity) | 15.0 / 25 |
The pillar pattern: Growth is the clear strength (5/6) — the tailwind is undeniable. Longevity is solid (4/5). Quality is the soft spot (7.5/12): returns barely clear the cost of capital and the business eats capital to grow. Price is the only thing standing between this and an interesting setup — and right now it stands tall in the way.
Buffett lens (the Berkshire-letters read)
| # | Test | Verdict | Evidence |
|---|---|---|---|
| 1 | Good boat? (business > management) | PARTIAL | A Good boat — decent RoCE (16.7%) but heavy capital to grow. Not Great, not Gruesome. |
| 2 | Moat + franchise + pricing power | FAIL | Price-taker, not -setter. Pass-through “not on day zero.” OPM swings 4–13%. No franchise. |
| 3 | See’s test — high returns on little capital | FAIL | The opposite of See’s. FCF negative three of last five years; ₹800cr PCB capex ahead. |
| 4 | Capital allocation — one-dollar test | PARTIAL | Retained earnings are compounding book value, and value walked away from K-Solare; but RoE ~CoE means each retained rupee makes barely more than a rupee. |
| 5 | Owner-oriented, candid management | PASS | Beats margin guidance, plain-spoken on costs and working capital, admits caution honestly. |
| 6 | Integrity / no “credit P&L, debit B/S” | PASS | FY26 OCF (₹290 cr) backs profit; debt cut; zero pledging. (Earlier cash-burn years now corrected.) |
| 7 | Circle of competence / predictability | PARTIAL | The trade is predictable (build electronics); the margins and mix are not — and the PCB pivot adds a new, unproven business. |
| 8 | Mr. Market — gift or trap now? | FAIL | Priced for perfection: ~80x earnings, 9x book, all-time high, euphoric narrative. A trap-shaped price, not a gift. |
| 9 | Patience / compounding runway | PASS | Long runway: tiny share of a vast market, decade-plus to grow into. |
| 10 | The honest red flag | (below) | See paragraph. |
The See’s test, spelled out: Buffett’s See’s Candies took $25m to buy and only $32m more over 35 years, yet threw off $1.35bn. Syrma is the mirror image. To turn ₹3,154 cr of sales (FY24) into ₹4,819 cr (FY26), it has poured capital into fixed assets (up from ₹532 cr in FY23 to ₹1,463 cr in FY26) and is about to spend ₹800 cr more on PCBs. Growth here is bought, not gifted. That is the defining feature of a “Good” business, and it’s why the See’s test fails.
The one-dollar test, spelled out: has each retained rupee created at least a rupee of market value? Net worth roughly tripled from ~₹950 cr (FY21) to ₹2,863 cr (FY26) while the market cap exploded to ₹25,724 cr — so on price, spectacularly yes. But that’s the market’s verdict in a euphoric mood, not the economics. On economics, Economic Profit is just ₹54 cr (RoE 13.9% vs CoE 12% on ₹2,863 cr net worth) — each retained rupee earns barely 2% above its cost. The reinvestment is value-accretive but only thinly so. The market is paying as if the spread were far wider than it is.
The honest red flag (test 10): The strongest reason this may not be a wealth creator: it’s a thin-margin, capital-hungry contract manufacturer in an increasingly crowded trade, earning returns only a whisker above its cost of capital — and it’s priced as if it were a high-moat compounder. Do the numbers refute it? Only partly. They support the growth and the clean balance sheet, and the mix-shift toward ODM/defence/exports is genuinely lifting margins. But they do not yet refute the core worry: that EMS, sector-wide, sees revenue boom while margins drift down as competition floods in. If the PCB bet doesn’t lift structural returns, this stays a Good business forever — and a Good business at 80x is the trap, not the prize.
The framework metrics
- Economic Profit = Net Worth ₹2,863 cr × (RoE 13.9% − CoE 12%) = +₹54 cr → thinly creating value (CoE = 12%, the Indian benchmark mid-point).
- Terms of Trade = Debtor days 139 ÷ Payable days 199 = ~70% → favourable on a days basis (suppliers part-fund it), but working-capital days jumped 60→107 — a yellow flag from the acquisitions/defence mix.
- 5-yr Payback = Mcap ₹25,724 cr ÷ projected cumulative 5-yr PAT (~₹4,067 cr, assuming 30% PAT CAGR off FY26’s ₹346 cr) = ~6.3x → far above the <1x multibagger signal.
- PEG = P/E 80 ÷ 5-yr PAT growth ~38% = ~2.1x (forward, on ~35% growth, also ~2x). Price discipline not satisfied.
- RoE − CoE spread = +1.9% (thin). RoE > 15% in roughly 2 of the last 10 years — fails the ≥7-of-10 moat test.
- Consistent vs Volatile = Volatile. PAT path (92→69→79→123→124→184→346) shows two down-years and margin swings — value this on book/growth, not a stable P/E.
Peer comparison
| Company | Mcap (₹cr) | CMP (₹) | P/E | P/B | RoE | RoCE | OPM | Latest sales (₹cr) |
|---|---|---|---|---|---|---|---|---|
| Syrma SGS | 25,724 | 1,334 | 80.1 | 9.0 | 13.9% | 16.7% | 11% | 4,819 |
| Dixon Technologies | 76,461 | 12,517 | 53.2 | 16.3 | 37.4% | 42.0% | 4% | 48,873 |
| Kaynes Technology | 21,807 | 3,253 | 59.6 | 4.6 | 9.6% | 13.2% | 16% | 3,626 |
| Avalon Technologies | 11,652 | 1,745 | 103 | 16.2 | 16.9% | 19.5% | 11% | 1,603 |
| Cyient DLM | 3,760 | 474 | 51.3 | 3.7 | 7.5% | 9.9% | 10% | 1,261 |
Peer ratios from each company’s screener snapshot, 2026-06-20.
The relative read is unflattering, and it flips nothing in Syrma’s favour. The whole sector is expensive (50–100x earnings) — so Syrma’s 80x isn’t an outlier, but it’s at the dear end. Dixon earns 3–4× Syrma’s returns (RoE 37%, RoCE 42%) at a lower P/E (53x) on far thinner operating margins — the market is paying Dixon’s high multiple for its astonishing capital efficiency, which Syrma simply doesn’t have. Kaynes carries fatter operating margins (16% vs 11%) thanks to its aerospace/defence/semis tilt, at a cheaper P/E and P/B. Avalon is even pricier than Syrma but smaller. Syrma’s distinctive edge in this set is its diversification (five verticals, heavy exports, no single-customer dependence) and its just-completed balance-sheet clean-up — but on the two numbers that matter most, returns and price, it is neither the best operator nor the cheapest stock in its asset class.
Latest quarter & what’s happening now
Q4 FY26 (reported 12 May 2026): the strongest quarter ever. Revenue ₹1,477 cr (+56% YoY, +16% QoQ), EBITDA ₹174 cr (+51%), PAT ₹119 cr (+67%). For the full year: revenue ₹4,819–4,857 cr (+27%), PAT ₹346 cr (+87%), and the headline turn — from net debt ₹264 cr to net cash ₹467 cr, with operating cash flow of ₹290 cr (HARD — Q4 FY26 concall). Notably, Syrma’s profit grew 67% in the quarter while peers Dixon (−36%) and Kaynes (−21%) saw profits fall — the best profit conversion in the pack this quarter (MEDIUM — EBC/MarketsMojo).
Concall takeaways: (1) FY27 guidance is ~35% revenue growth / ₹700 cr EBITDA at 10.5–11% margin — top-line ambitious, margin deliberately cautious on supply-chain inflation (MEDIUM). (2) The PCB project is on track for late-FY27/FY28 commissioning; total program ₹800 cr+ across phases (MEDIUM). (3) K-Solare solar JV dropped — discipline, charged off, renewable-inverter intent kept (HARD). (4) Order book ₹6,400–6,600 cr, ~24% implied near-term growth, the rest to be filled by short-cycle orders (MEDIUM).
Where the two lenses agree — and disagree
They mostly agree, which is itself the signal. Both call it a Good, not Great, business: QGLP’s Quality pillar is the weak one (7.5/12), and Buffett’s See’s test and moat test both fail. Both flag the price as the problem (Q24–25 = 0.5/2; Buffett test 8 = FAIL). Both credit the management (QGLP Q7–12 = 4/6; Buffett tests 5–6 = PASS).
Where they part is instructive: QGLP’s checklist is kinder to the growth story than Buffett’s economics are. The checklist rewards the tailwind, the market-share gains, and the operating leverage (Growth 5/6) — all true. But Buffett’s lens cuts straight to the marrow: a business that must buy its growth with capital, earning barely above its cost of capital, is a Good boat whose owner gets rich only if (a) the runway is very long and (b) he didn’t overpay at the dock. Trust the Buffett flag here: the growth is real, but the quality of that growth — its return on the capital it consumes — is the thing the euphoric price is ignoring.
The price as a current phenomenon
This section judges the price, not the business. The business verdict above (a Good, capable, tailwind-blessed compounder) is settled and would not move if the quote halved tomorrow. Here we only ask what the market charges today.
The margin-of-safety band. The framework’s arithmetic is unsentimental. For QGLP’s Price pillar to clear — PEG ≤ 1x on ~35% growth — you’d need a P/E near 35, which against FY26 EPS of ₹16.48 implies roughly ₹580–₹600. A 5-yr payback approaching a sane 2–2.5x (still demanding for this asset class) points to a similar ₹600–₹820 zone. So the band where a patient value investor’s discipline is satisfied is roughly ₹600–₹820 — well below today’s ₹1,334. That is not a price target; it’s the arithmetic of where the quality becomes worth owning on these frameworks’ terms.
Mr. Market’s mood. Today he is plainly greedy on this name. The stock is up ~157% off its June-2025 low, sitting at an all-time high, on a roaring “India electronics supercycle / Make-in-India / China+1” narrative. Sell-side is overwhelmingly bullish (19 of 22 “buy”) and consensus fair-value estimates have themselves been chased upward (from ~₹960 to ~₹1,170) as the price ran — a classic sign of narrative leading the numbers, not the reverse (SOFT — Simply Wall St/Investing.com consensus). A genuinely strong Q4 lit the fuse, but the valuation re-rating has outrun the earnings re-rating.
The tension, stated plainly: this is the case of a Good business at an un-Good price — the inverse of the bargain. A wonderful business can sit at an unwonderful price, and that is what we have: nothing is wrong with the company, but a lot is priced into the quote. And remember — this entire reading can change next week without a single bolt changing on the factory floor. A sector de-rating, a soft quarter, or a PCB-timeline slip would reset the mood; the Good business in Box 1 would be exactly as Good the morning after.
Conviction texture
The bull case, at its strongest: India’s EMS boom is real and early, Syrma is firing on every vertical, just turned cash-generative, holds net cash and an AA rating, is run by honest lifelong operators with genuine discipline (they walked away from a deal), and is climbing the value ladder into stickier, fatter-margin niches — defence, medtech ODM, exports, and its own PCBs with a government moat. If the PCB bet lands and the mix-shift holds, structural returns rise, the “Good→Great” transition begins, and today’s price looks cheap in hindsight. It out-earned every major peer this quarter.
The bear case, at its strongest: it’s a thin-margin contract manufacturer earning barely its cost of capital, in a trade getting more crowded by the quarter (Dixon, Kaynes, Amber, L&T), where the whole sector is told revenue will boom while margins drift down. It must spend ₹800 cr on a capital-heavy, historically-low-return PCB business just to defend its position. And it’s priced at 80x earnings / 9x book / 6x payback — a Great-business multiple stapled to a Good business. The margin of safety isn’t thin; it’s absent.
What the numbers actually support: a Good business (14.5/23, EP barely positive, returns ~CoE) on a real tailwind, fairly-to-richly run, expensively priced. Not Gruesome — the cash turn and the clean balance sheet are real. Not Great — the See’s test and moat test fail on the numbers. The honest verdict is that the business deserves respect and the price deserves patience.
The three things to watch that would tip it: (1) the PCB plant’s commissioning and first-year returns — the whole Good-vs-Great question hinges here; (2) whether FY27 EBITDA margin holds ≥11% or sinks toward the commodity 8–9%; (3) whether operating cash flow stays positive through the capex spree. No buy/sell here — just the boat, the captain, and the price of the seat, kept honestly apart.
Sources
- Screener snapshot: https://www.screener.in/company/SYRMA/consolidated/ (fetched 2026-06-20). Peers: Dixon, Kaynes, Avalon, Cyient DLM screener snapshots (same date).
- Concalls: Q4 FY26 (held 12 May 2026), Q3 FY26 (held 30 Jan 2026) — Syrma SGS investor relations / BSE filings.
- Annual reports: FY25, FY24 (key sections) — BSE corporate filings.
- Management/promoter research (dated, sourced): Tandon Corporation lineage (Wikipedia); QIP ₹1,000 cr Aug 2025 and promoter-dilution mechanism (Trendlyne, Business Standard, ScanX); Elcome 60% / ₹235 cr Dec 2025 (Business Upturn, Syrma); K-Solare JV dropped 11 May 2026 (Energetica, SolarQuarter); India Ratings AA upgrade 5 May 2026 (Whalesbook); IPO Aug 2022 (Chittorgarh).
- Industry / crux: India EMS sector growth and margin pressure (Kotak Securities, EBC, Whalesbook, Zerodha Daily Brief); ECMS scheme & PCB import-substitution (PIB, CNBC, Tribune); Syrma PCB plant / Shinhyup partnership (Business Standard, Adiva).
- Price/sentiment: all-time high ₹1,355, +157% off ₹499 low, ~80x P/E, consensus “Strong Buy” with fair-value chased to ~₹1,170 (MarketsMojo, Business Standard, Simply Wall St, Investing.com).
- Assumptions used: Cost of Equity = 12%; PAT 5-yr CAGR ~38% (computed from screener Net Profit row); forward PAT growth ~30–35% (management guidance); 5-yr payback projected at 30% PAT CAGR.
No buy/sell/hold recommendation. The deliverable is a business-quality verdict, a margin-of-safety price band, and two-sided conviction. As of 2026-06-20.